| 191.82 3.8 (2.02%) | 02-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 236.41 | 1-year : | 276.13 |
| Resists | First : | 202.41 | Second : | 236.41 |
| Pivot price | 193.57  |
|||
| Supports | First : | 182.4 | Second : | 170.03 |
| MAs | MA(5) : | 192.5 |
MA(20) : | 190.5 |
| MA(100) : | 171.4 |
MA(250) : | 147.89 |
|
| MACD | MACD : | 3.5 |
Signal : | 4.2 |
| %K %D | K(14,3) : | 38.8 |
D(3) : | 51.6 |
| RSI | RSI(14): 55.6 |
|||
| 52-week | High : | 202.41 | Low : | 110.04 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BIIB ] has closed above bottom band by 40.2%. Bollinger Bands are 41.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 190.95 - 192.51 | 192.51 - 193.55 |
| Low: | 182.68 - 184.39 | 184.39 - 185.54 |
| Close: | 185.77 - 188.43 | 188.43 - 190.22 |
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Fri, 27 Feb 2026
Biogen’s BIIB080 Readout Tests Alzheimer’s Hopes And Investor Sentiment - simplywall.st
Fri, 27 Feb 2026
Generali Investments Management Co LLC Grows Holdings in Biogen Inc. $BIIB - MarketBeat
Fri, 27 Feb 2026
Fox Run Management L.L.C. Has $976,000 Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Thu, 26 Feb 2026
10,006 Shares in Biogen Inc. $BIIB Acquired by K.J. Harrison & Partners Inc - MarketBeat
Wed, 25 Feb 2026
March 2027 Options Now Available For Biogen (BIIB) - Nasdaq
Fri, 20 Feb 2026
Barclays Initiates Coverage of Biogen (BIIB) with Equal-Weight Recommendation - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 147 (M) |
| Shares Float | 146 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 97.8 (%) |
| Shares Short | 4,690 (K) |
| Shares Short P.Month | 4,470 (K) |
| EPS | 8.78 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 124.36 |
| Profit Margin | 13 % |
| Operating Margin | 19.6 % |
| Return on Assets (ttm) | 6.1 % |
| Return on Equity (ttm) | 7.3 % |
| Qtrly Rev. Growth | -7.1 % |
| Gross Profit (p.s.) | 53.21 |
| Sales Per Share | 67.38 |
| EBITDA (p.s.) | 24.52 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 2,200 (M) |
| Levered Free Cash Flow | 1,980 (M) |
| PE Ratio | 21.87 |
| PEG Ratio | 0 |
| Price to Book value | 1.54 |
| Price to Sales | 2.85 |
| Price to Cash Flow | 12.82 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|